Jonathan W. Friedberg, M.D., M.M.Sc.

Jonathan W. Friedberg, M.D., M.M.Sc.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 704
Rochester, NY 14642

Administrative: (585) 275-4911
Fax: (585) 273-5761
Office: (585) 275-5823

Professional Bio

Jonathan W. Friedberg, M.D., is Director of the James P. Wilmot Cancer Center, Chief of Hematology/Oncology and Director of Hematological Malignancies Clinical Research.



He is a driving force behind the operations of our clinical programs and a key member of the center's lymphoma Specialized Program of Research Excellence, funded by the National Cancer Institute.

Friedberg is a member of the lymphoma committee in the Southwest Oncology Group, and serves as principal investigator on many local and national lymphoma treatment protocols for both Hodgkin lymphoma and non-Hodgkin's lymphoma.

Dr. Friedberg received his medical degree from Harvard Medical School. His postgraduate training included an internship and residency at Massachusetts General Hospital. He also completed a medical oncology and hematology fellowship at Dana-Farber/Partners Cancer Care in Boston. Dr. Friedberg also has an M.M.Sc. degree from Harvard Medical School in clinical investigation. He holds subspecialty certification in Medical Oncology and Hematology.

His research interests focus on development of novel therapies for patients with lymphoma. Most recently, he was awarded the Scholar in Clinical Research award from the Leukemia & Lymphoma Society, based upon his work with an oral inhibitor of a protein called Syk, which demonstrated efficacy in the treatment of several different forms of lymphoma, and was selected as a plenary presentation at the annual meeting of the American Society of Hematology.

Awards & Honors (National)

Lawrence A. Kohn Senior Teaching Fellow | Outstanding Teaching Contributions, Department of Medicine, Univ 2004 - 2006

Awards & Honors (Local)

Faculty Academic Mentoring Award | University of Rochester School of Medicine and Dentistry | University of Rochester 2012
Scholar in Clinical Research | Leukemia and Lymphoma Society 2008 - 2008
America's Top Doctors Selection 2008 - 2008
Jacob Gitleman Award | Gilda's Club and Cancer Action | Rochester, NY 2007 - 2007
Clinical Investigator Career Development Award | Lymphoma Research Foundation 2003 - 2003
Clinical Oncology Research Fellowship " Immunotherapy of Hodgkin's Disease" | Berlex Oncology Foundation 2001 - 2003
Rising stars program for innovative research | Dunkin Donuts and Dana-Farber Cancer Institute Department of Adu 2001 - 2003

Recent Journal Articles

Showing the 5 most recent journal articles. 113 available »

2014 Nov 24
Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW, Press O, LeBlanc M, Cerhan JR, Novak A, Ansell S. "Elevated serum levels of IL-2R, IL-1RA and CXCL9 are associated with a poor prognosis in follicular lymphoma." Blood. 2014 Nov 24; Epub 2014 Nov 24.
2014 Nov 13
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, LeBlanc M, Fisher RI. "Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high risk limited stage aggressive B-cell lymphoma: SWOG S0313." Blood. 2014 Nov 13; Epub 2014 Nov 13.
2014 Nov 5
Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Taylor M, Friedberg JW, Koff JL, Link BK, Cerhan JR, Dawson KL, Flowers CR. "Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States." Leukemia & lymphoma. 2014 Nov 5; :1-8. Epub 2014 Nov 05.
2014 Oct 1
Friedberg JW. "End of rituximab maintenance for low-tumor burden follicular lymphoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Oct 1; 32(28):3093-5. Epub 2014 Aug 25.
2014 Oct
Gopal AK, Bartlett NL, Forero-Torres A, Younes A, Chen R, Friedberg JW, Matous JV, Shustov AR, Smith SE, Zain J, O'Meara MM, Fanale MA. "Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy." Leukemia & lymphoma. 2014 Oct; 55(10):2328-34. Epub 2014 Feb 24.

Current Appointments

Director - Cancer Center - Primary Administrative
Samuel E. Durand Chair in Medicine - Department of Medicine (SMD)
Professor - Department of Medicine, Hematology/Oncology (SMD) - Primary
Professor - Cancer Center

Specialties

Hematology - American Board of Internal Medicine
Medical Oncology - American Board of Internal Medicine
Internal Medicine - American Board of Internal Medicine

Education

MS | Clinical Investigation | Harvard Medical School2001
MD | Medicine | Harvard Medical School1994
BA | Biology | Williams College1990

Post-Doctoral Training & Residency

Fellowship in Hematology/Oncology at Dana-Farber Cancer Institute07/01/1997 - 06/01/1999
Residency in Internal Medicine at Massachusetts General Hospital07/01/1995 - 06/01/1997
Internship in Internal Medicine at Massachusetts General Hospital07/01/1994 - 06/30/1995